Assays Approved to Diagnose Myocardial Infarction, Risk Assessment
Two new assays that aid physicians in the diagnosis of myocardial infarction and the assessment of risk in patients with acute coronary syndrome have just received FDA clearance.
The TnI-Ultra assays have been cleared on the ADVIA IMS 800i and ADVIA Centaur Immunoassay System. These assays are the first fully-automated Troponin assays to meet both the European Society of Cardiology and ACC recommendations of a less than or equal to 10 percent level of imprecision at the 99th percentile of a healthy population.
This strong concordance between assays allows for equivalent results in core and satellite laboratory situations. The high degree of precision seen with the TnI-Ultra assays is expected to show an increased level of accuracy, contributing to improved patient care in those suspected of MI.
More like this
- New Sepsis Assay Targeted for Siemens ADVIA Centaur and Immulite Immunoassay Analyzers
- Siemens Among the First Selected for Integrated Portfolio
- Point-of-Care Troponin-I Analyzer Begins Final Comparative Testing
- New Test May Reduce Time in Diagnosing Heart Attacks, Assist in Determining Risk for Future MI
- Biomarker of Myocardial Ischemia Now Used to Diagnose Acute Coronary Syndrome